mobile Health Forschung

Datenqualität auf akademischem Standard

In Zusammenarbeit mit Krebsforschungszentren, Kliniken und dem Life Sciences Bereich engagieren wir uns für Patienten-Empowerment (Mitwirkung und Mitentscheidung im Gesundheitsbereich) und Datenerhebung auf regulatorischem Studienniveau. Die von Patient*innen erhobenen Symptome in Verbindung mit klinischen Daten eröffnen dabei neue Erkenntnisse und Möglichkeiten für die medizinische Versorgung und Forschung (real-world evidence).

Mehr als 1000 Patient*innen sind bereits mit unserem System verbunden.

So wird die Entwicklung neuer, gezielter Methoden zur Behandlung von Krebs und Krankheiten ermöglicht.

Als Patient*in

Sie unterstützen die Krebsforschung, indem Sie Ihre Daten in der App in pseudonymisierter Form freigeben. So tragen Sie mit Ihrer Patientenerfahrung zur Verbesserung der Behandlung bei – selbstverständlich freiwillig.

Als Ärzt*in

Sie unterstützen die Krebsforschung, indem Sie Ihre Patient*innen bei der Nutzung der App unterstützen und sich an eHealth-Studien und Registern beteiligen.

Co-Creation

Zusammen neue Forschungsansätze initiieren – Sie haben eine Idee? Wir die nötigen Tools, Kontakte und Erfahrung.

Publications: A Selection

Efficiency of the "Medidux" Smartphone App for Demission Management in Patients Medicated in Acute Admission Unit (AAU) (EffiDux)

Ongoing

This clinical trial evaluates whether using the medidux app for symptom and vital sign monitoring after discharge from Acute Admission Units can reduce short-term readmissions and emergency visits in non-urgent patients. By comparing outcomes between app users and those receiving standard care, the study aims to determine if digital follow-up improves post-discharge management and reduces unnecessary healthcare utilization.

Swiss CanOn – Swiss Cannabis Oncology

Ongoing

The Swiss CanOn registry uses the medidux platform to collect real-world data on the use of cannabis-based medicinal products in cancer care, combining physician-reported prescriptions with patient-reported outcomes via a smartphone app. This integrative approach aims to improve clinical understanding, support safer use, and inform future access to cannabinoid therapies.

Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes

JMIR Cancer, 2024
10.2196/54178

Using the medidux app, patients treated with the HER2-targeted biosimilar Ogivri reported side effects and well-being outcomes equivalent to those of historical cohorts treated with Herceptin. Symptom burden was generally low and consistent across both groups. This real-world study shows that integrating an ePRO platform like medidux into care settings can reliably capture patient experiences, supporting informed treatment decisions and validating therapeutic equivalence in daily practice.

Effect of Collaborative Review of Electronic Patient-Reported Outcomes for Shared Reporting in Breast Cancer Patients: Descriptive Comparative Study

JMIR Cancer, 2021
10.2196/26950

This comparative study of two Consilium app versions showed that prompting structured patient-physician reviews significantly increased the number and quality of electronic symptom entries. Patients using the newer version reported more frequently and found the app more helpful during consultations. These insights directly informed the development of medidux, reinforcing that integrating shared digital monitoring into routine care can improve the accuracy of ePROs and foster more meaningful clinical dialogue.

Consilium Smartphone App for Real-World Electronically Captured Patient-Reported Outcome Monitoring in Cancer Patients Undergoing anti-PD-L1-Directed Treatment

Case Rep Oncol, 2020
10.1159/000507345

Six patients undergoing immunotherapy for advanced cancers used the Consilium app, medidux‘ predecessor, to log symptoms over three months, contributing over 1,200 real-time entries. Common symptoms like fatigue and shortness of breath were documented with detailed severity levels, triggering alerts without requiring unplanned visits. High satisfaction among patients and physicians highlighted how shared digital reporting via medidux can safely support outpatient care and improve the quality of clinical interactions.

A Mobile App to Stabilize Daily Functional Activity of Breast Cancer Patients in Collaboration With the Physician: A Randomized Controlled Clinical Trial

JMIR, 2016
10.2196/jmir.6414

In a randomized study of breast cancer patients undergoing chemotherapy, those who used Consilium (now medidux) to track symptoms and reviewed their data with a physician maintained stable daily functioning – unlike those without such review. Both groups using the app reported more adverse events than via traditional questionnaires provided only during planned visits, but supervised users made more precise, focused entries. These findings demonstrate medidux can support patient well-being and enhance symptom awareness during treatment.

Prof. Dr. med. Andreas Trojan

CEO, Chief Medical Officer, Founder

Team and expertise

Products developed by qualified experts

Andreas holds a position as senior oncologist at both, the Brust- and the OnkoZentrum Zürich in Switzerland. Moreover, he is a titular-professor at the medical faculty of the University of Zurich. Treating cancer patients over more than 20 years clearly indicated that the consideration of PROs is key for treatment success. Driven by this conviction Andreas founded Mobile Health AG and started to develop Consilium Care™, an App for patients to capture well-being and therapy side effects. The current large observational study, started in 2018, investigates the efficiency of the “Consilium Care™” smartphone App for detecting symptoms and treatment side effects in cancer patients depending on form of medication application, age and outpatient characteristics.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Prof. Dr. med. Andreas Trojan

Individual patient

Doctor

Consilium Care™ platform

1. Patients track their health with Consilium Care™

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation.

3. Treatment plans can be adjusted due to insights